When I wrote this blog, I felt that
this was important and that Dr. Kendrick was correct, but I did not
realize that I would see something so quickly from a United States
authority. The Mayo Clinic in Rochester, Minnesota published a study
in the January issue of Mayo Clinic Proceedings showing that most
clinical practice guidelines are based on lower-quality medical
evidence and a failure to disclose authors' conflicts of interest.
Then I had to realize that in early
2013 the American Association of Clinical Endocrinologists led by the
nefarious Dr. Garber was attempting to have universal acceptance of
the diabetes algorithms without disclosure of the authors' conflicts
of interest. Fortunately, for patients, a couple of articles made it
necessary for them to publish a consensus statement, which also
listed the conflicts of interest of which Dr. Garber had plenty.
This is important enough to quote,
““Guidelines are meant to create a succinct roadmap for the
diagnosis and treatment of medical conditions by analyzing and
summarizing the increasingly abundant medical research,” write
Joseph Feuerstein, MD, and colleagues from Beth Israel Deaconess
Medical Center. “Guidelines are used as a means to establish a
standard of care … However, a guideline’s validity is rooted in
its development process.””
Most of the current practice guidelines
in publication do not satisfy criteria that represent trustworthiness
as defined by the Institute of Medicine. This definitely means that
more attention needs to be paid to potential conflicts of interest
among guideline authors and guideline development panels.
How much longer will the medical and
other groups let the literature continue to grow that documents the
existence of potential conflicts of interest reported for authors or
members of guideline development panels? I may be wrong, but it
seems that they are staying quiet to earn their place on one of these
panels or to keep the side income flowing that they are currently
receiving.
“As a result, the influence of
external activities such as consulting or speaking fees, research
grant funding and stock ownership has the potential to create
significant bias and uncertainty for issued recommendations.”
Who pays the price for these greedy doctors and panel members. If
you don't think that we as patients will suffer for the guidelines
that overreach and promote more medications that have not been
clinically proven to be beneficial, then go ahead and take the higher
dosage and the extra medication the guidelines insist that we need.
No comments:
Post a Comment